TCM Biotech has received FDA Breakthrough Device Designation for CatCHimera, a liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma using HBV–host genome integration biomarkers.
The goal is to support the implementation of Bio-Rad’s ddPCR technology for tumor-informed MRD monitoring of those with solid tumor cancer.
Research shows a noninvasive ddPCR test can help physicians diagnose and monitor the clinical progress of patients with gliomas.
A potential alternative to immunohistochemistry for predicting patients’ response to anti-PD-L1 therapy is to use testing based on the droplet digital polymerase chain reaction technique to detect changes in the mRNA expression levels in patients’ blood.
Read More
The highly multiplexed ddPCR-based assay is currently in use by biopharma partners.
Read More